Skip to content

Efficacy and Safety of Multiple Faecal Microbiota Transfers in Acute Pouchitis

Efficacy and Safety of Multiple Faecal Microbiota Transfers in Acute Pouchitis - FMT-pouchitis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49333
Enrollment
20
Registered
2020-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammation of the pouch reservoir Pouchitis

Interventions

Patients will receive a multiple faecal microbiota transfers from healthy, carefully selected donors.

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • IPAA for ulcerative colitis • Episode of acute pouchitis, defined as a PDAI >= 7, and endoscopic subscore of > 2 • History of at least one episode of pouchitis, which necessitated antibiotic treatment.

Exclusion criteria

Exclusion criteria: - Pouchitis due to surgery related conditions (i.e. abscess, fistula. sinus of the pouch), identified by endoscopic assessment of the pouch - Crohn's Disease - Patients with signs of severe systemic inflammation (at least two of the following symptoms: temperature > 38.5 *C, tachycardia > 100 bpm (after rehydration), systolic blood pressure

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the proportion of patients in clinical and endoscopic remission at week 8.

Secondary

MeasureTime frame
The main secondary endpoints are antibiotic-free clinical and endoscopic remission at week 52, and changes in microbiota signature, functional profiling as well as metabolic output from baseline to week 8 and week 52. To study the speed of clinical remission induction of pouchitis after FMT.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)